日本語English简体中文 繁體中文

300558 Betta Pharmaceuticals Co., Ltd.贝达药业Shenzhen Stock Exchange

13 posts

Betta Pharmaceuticals Co., Ltd. (300558) at a glance

Code
300558
Company
Betta Pharmaceuticals Co., Ltd.
Local name
贝达药业
Market
Shenzhen Stock Exchange
Share price
CN¥46.77 -0.57 (-1.20%) Nov 9 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

Betta Pharmaceuticals Co., Ltd. (300558) Stock Price History

Betta Pharmaceuticals Co., Ltd. closed at CN¥46.77 on Nov 9, 2026, −3.4% over 1 month, −13.8% over 1 year.

2026-10-16 新薬・製品の承認 关于BPI-572270胶囊药品联用临床试验申请获得受理的公告2026-10-19 新薬・製品の承認 关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二…2026-10-20 新薬・製品の承認 关于注射用BPI-585771临床试验申请获得受理公告2026-10-26 保有株の担保差入 关于股东股份质押变动的公告2026-10-29 四半期報告 2026年三季度报告 / 取締役会決議 第五届董事会第五次会议决议公告 / 関連当事者取引 关于增加2026年日常关联交易预计的公告 / 関連当事者取引 关于与杭州晟斯生物签订《技术转让协议》暨关联交易的公告 / 資産の減損 关于计提资产减值准备的公告2026-10-30 保有株の担保差入 关于股东股份质押变动的公告CN¥49.05CN¥39.90Oct 9Nov 9
Price5-day MA25-day MASSE CompositeDisclosures
1-Month HighCN¥49.05Nov 5
1-Month LowCN¥39.90Oct 27
1-Week Change+0.5%vs Nov 2
1-Month Change−3.4%vs Oct 9

If you had invested CN¥10,000 1 month ago, it would be worth CN¥9,657 today (−3.4%).Price change only; dividends and fees are not included.

Over the same period the SSE Composite moved −4.3%, while this stock moved −3.4%.

Last 10 Trading Days

DateCloseChange% Change
Nov 9 (Mon)CN¥46.77−0.57−1.20%
Nov 6 (Fri)CN¥47.34−1.71−3.49%
Nov 5 (Thu)CN¥49.05+0.78+1.62%
Nov 4 (Wed)CN¥48.27+3.40+7.58%
Nov 3 (Tue)CN¥44.87−1.65−3.55%
Nov 2 (Mon)CN¥46.52+6.42+16.01%
Oct 30 (Fri)CN¥40.10+0.06+0.15%
Oct 29 (Thu)CN¥40.04−0.83−2.03%
Oct 28 (Wed)CN¥40.87+0.97+2.43%
Oct 27 (Tue)CN¥39.90−2.26−5.36%
2026-09-21 新薬・製品の承認 关于盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局人用药品委员…2026-09-28 新薬・製品の承認 关于BPI-572270胶囊获批在澳大利亚开展临床试验的公告2026-10-08 新薬・製品の承認 关于BPI-572270胶囊获得美国FDA新药临床试验批准的公告2026-10-16 新薬・製品の承認 关于BPI-572270胶囊药品联用临床试验申请获得受理的公告2026-10-19 新薬・製品の承認 关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二…2026-10-20 新薬・製品の承認 关于注射用BPI-585771临床试验申请获得受理公告2026-10-26 保有株の担保差入 关于股东股份质押变动的公告2026-10-29 四半期報告 2026年三季度报告 / 取締役会決議 第五届董事会第五次会议决议公告 / 関連当事者取引 关于增加2026年日常关联交易预计的公告 / 関連当事者取引 关于与杭州晟斯生物签订《技术转让协议》暨关联交易的公告 / 資産の減損 关于计提资产减值准备的公告2026-10-30 保有株の担保差入 关于股东股份质押变动的公告CN¥69.88CN¥39.90Aug 10Nov 9
Price5-day MA25-day MASSE CompositeDisclosures
3-Month HighCN¥69.88Aug 10
3-Month LowCN¥39.90Oct 27
1-Month Change−3.4%vs Oct 9
3-Month Change−33.4%vs Aug 7

If you had invested CN¥10,000 3 months ago, it would be worth CN¥6,693 today (−33.1%).Price change only; dividends and fees are not included.

Over the same period the SSE Composite moved −8.0%, while this stock moved −33.1%.

Last 10 Trading Days

DateCloseChange% Change
Nov 9 (Mon)CN¥46.77−0.57−1.20%
Nov 6 (Fri)CN¥47.34−1.71−3.49%
Nov 5 (Thu)CN¥49.05+0.78+1.62%
Nov 4 (Wed)CN¥48.27+3.40+7.58%
Nov 3 (Tue)CN¥44.87−1.65−3.55%
Nov 2 (Mon)CN¥46.52+6.42+16.01%
Oct 30 (Fri)CN¥40.10+0.06+0.15%
Oct 29 (Thu)CN¥40.04−0.83−2.03%
Oct 28 (Wed)CN¥40.87+0.97+2.43%
Oct 27 (Tue)CN¥39.90−2.26−5.36%
2026-09-21 新薬・製品の承認 关于盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局人用药品委员…2026-09-28 新薬・製品の承認 关于BPI-572270胶囊获批在澳大利亚开展临床试验的公告2026-10-08 新薬・製品の承認 关于BPI-572270胶囊获得美国FDA新药临床试验批准的公告2026-10-16 新薬・製品の承認 关于BPI-572270胶囊药品联用临床试验申请获得受理的公告2026-10-19 新薬・製品の承認 关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二…2026-10-20 新薬・製品の承認 关于注射用BPI-585771临床试验申请获得受理公告2026-10-26 保有株の担保差入 关于股东股份质押变动的公告2026-10-29 四半期報告 2026年三季度报告 / 取締役会決議 第五届董事会第五次会议决议公告 / 関連当事者取引 关于增加2026年日常关联交易预计的公告 / 関連当事者取引 关于与杭州晟斯生物签订《技术转让协议》暨关联交易的公告 / 資産の減損 关于计提资产减值准备的公告2026-10-30 保有株の担保差入 关于股东股份质押变动的公告CN¥72.90CN¥39.90May 11Nov 9
Price25-day MA75-day MASSE CompositeDisclosures
6-Month HighCN¥72.90Jul 3
6-Month LowCN¥39.90Oct 27
3-Month Change−33.4%vs Aug 7
6-Month Change−9.1%vs May 8

If you had invested CN¥10,000 6 months ago, it would be worth CN¥8,770 today (−12.3%).Price change only; dividends and fees are not included.

Over the same period the SSE Composite moved −13.6%, while this stock moved −12.3%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026CN¥46.77+16.6%
Oct 2026CN¥40.10−20.6%
Sep 2026CN¥50.48+0.0%
Aug 2026CN¥50.48−12.2%
Jul 2026CN¥57.50−11.6%
Jun 2026CN¥65.07+23.5%
May 2026CN¥52.68+1.4%
2026-09-21 新薬・製品の承認 关于盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局人用药品委员…2026-09-28 新薬・製品の承認 关于BPI-572270胶囊获批在澳大利亚开展临床试验的公告2026-10-08 新薬・製品の承認 关于BPI-572270胶囊获得美国FDA新药临床试验批准的公告2026-10-16 新薬・製品の承認 关于BPI-572270胶囊药品联用临床试验申请获得受理的公告2026-10-19 新薬・製品の承認 关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二…2026-10-20 新薬・製品の承認 关于注射用BPI-585771临床试验申请获得受理公告2026-10-26 保有株の担保差入 关于股东股份质押变动的公告2026-10-29 四半期報告 2026年三季度报告 / 取締役会決議 第五届董事会第五次会议决议公告 / 関連当事者取引 关于增加2026年日常关联交易预计的公告 / 関連当事者取引 关于与杭州晟斯生物签订《技术转让协议》暨关联交易的公告 / 資産の減損 关于计提资产减值准备的公告2026-10-30 保有株の担保差入 关于股东股份质押变动的公告CN¥72.90CN¥39.90Nov 10Nov 9
Price25-day MA75-day MASSE CompositeDisclosures
52-Week HighCN¥72.90Jul 3
52-Week LowCN¥39.90Oct 27
Year to Date+0.2%vs Dec 31
From 52-Week High−35.8%Jul 3

If you had invested CN¥10,000 1 year ago, it would be worth CN¥8,669 today (−13.3%).Price change only; dividends and fees are not included.

Over the same period the SSE Composite moved −9.2%, while this stock moved −13.3%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026CN¥46.77+16.6%
Oct 2026CN¥40.10−20.6%
Sep 2026CN¥50.48+0.0%
Aug 2026CN¥50.48−12.2%
Jul 2026CN¥57.50−11.6%
Jun 2026CN¥65.07+23.5%
May 2026CN¥52.68+1.4%
Apr 2026CN¥51.94+19.1%
Mar 2026CN¥43.60−5.2%
Feb 2026CN¥46.00−2.3%
Jan 2026CN¥47.07+0.8%
Dec 2025CN¥46.69−5.0%
Nov 2025CN¥49.15−13.6%
CN¥73.95CN¥31.60Nov 13, 2023Nov 9, 2026
Price13-week MA26-week MASSE Composite
3-Year HighCN¥73.95Sep 1, 2025
3-Year LowCN¥31.60Jul 15, 2024
Annualized Return−7.2%
Max Drawdown−46.0%

If you had invested CN¥10,000 3 years ago, it would be worth CN¥7,987 today (−20.1%).Price change only; dividends and fees are not included.

Over the same period the SSE Composite moved +19.5%, while this stock moved −20.1%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)CN¥46.77+0.2%
2025CN¥46.69―
CN¥89.13CN¥31.60Nov 15, 2021Nov 9, 2026
Price13-week MA26-week MASSE Composite
5-Year HighCN¥89.13Nov 15, 2021
5-Year LowCN¥31.60Jul 15, 2024
Annualized Return−12.1%
Max Drawdown−64.5%

If you had invested CN¥10,000 5 years ago, it would be worth CN¥5,247 today (−47.5%).Price change only; dividends and fees are not included.

Over the same period the SSE Composite moved +2.5%, while this stock moved −47.5%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)CN¥46.77+0.2%
2025CN¥46.69―
CN¥139.98CN¥30.10Dec 1, 2016Nov 9, 2026
Price1-year MA2-year MASSE Composite
All-Time HighCN¥139.98Jun 2020
All-Time LowCN¥30.10Jan 2019
Total Change−36.6%vs Dec 2016
Annualized Return−4.5%

If you had invested CN¥10,000 in Dec 2016, it would be worth CN¥6,337 today (−36.6%).Price change only; dividends and fees are not included.

Over the same period the SSE Composite moved +17.6%, while this stock moved −36.6%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)CN¥46.77+0.2%
2025CN¥46.69−13.4%
2024CN¥53.93+4.6%
2023CN¥51.55+4.6%
2022CN¥49.27−38.3%
2021CN¥79.83−25.6%
2020CN¥107.37+63.4%
2019CN¥65.70+105.5%
2018CN¥31.97−49.5%
2017CN¥63.29−14.2%
2016CN¥73.80―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Dec 2016). Please check the latest prices before trading.

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No.13 Disclosure 2026/10/30 09:00
保有株の担保差入
关于股东股份质押变动的公告
Delete
No.12 Disclosure 2026/10/29 09:00
資産の減損
关于计提资产减值准备的公告
Delete
No.11 Disclosure 2026/10/29 09:00
関連当事者取引
关于与杭州晟斯生物签订《技术转让协议》暨关联交易的公告
Delete
No.10 Disclosure 2026/10/29 09:00
関連当事者取引
关于增加2026年日常关联交易预计的公告
Delete
No.9 Disclosure 2026/10/29 09:00
取締役会決議
第五届董事会第五次会议决议公告
Delete
No.8 Disclosure 2026/10/29 09:00
四半期報告
2026年三季度报告
Delete
No.7 Disclosure 2026/10/26 09:00
保有株の担保差入
关于股东股份质押变动的公告
Delete
No.6 Disclosure 2026/10/20 09:00
新薬・製品の承認
关于注射用BPI-585771临床试验申请获得受理公告
Delete
No.5 Disclosure 2026/10/19 09:00
新薬・製品の承認
关于合作伙伴EyePoint公布DURAVYU治疗湿性年龄相关性黄斑变性第二项关键Ⅲ期临床试验数据的公告
Delete
No.4 Disclosure 2026/10/16 09:00
新薬・製品の承認
关于BPI-572270胶囊药品联用临床试验申请获得受理的公告
Delete
No.3 Disclosure 2026/10/08 09:00
新薬・製品の承認
关于BPI-572270胶囊获得美国FDA新药临床试验批准的公告
Delete
No.2 Disclosure 2026/09/28 09:00
新薬・製品の承認
关于BPI-572270胶囊获批在澳大利亚开展临床试验的公告
Delete
No.1 Disclosure 2026/09/21 09:00
新薬・製品の承認
关于盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局人用药品委员会积极意见的公告
Delete

Write on the Betta Pharmaceuticals Co., Ltd. board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Chinese stocks in English

Chinese Stock Message Board: stocks available in English

Other boards in English